TheraSphere.com provides unique resources and targeted information
about this innovative radioembolization therapy
OTTAWA, Ontario--(BUSINESS WIRE)--Mar. 5, 2013--
Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and
services for the prevention, diagnosis and treatment of disease,
announced today that it has launched a new and improved, intuitive,
website, providing liver cancer patients and physicians with customized
TheraSphere® resources that include medical and clinical information,
convenient online ordering, and innovative digital resources.
“The new website highlights the resources and programs that make
TheraSphere® a truly unique treatment offering,” said Steve West,
Nordion CEO and Chief Operating Officer, Targeted Therapies. “With
physicians and patients increasingly seeking digital delivery of
treatment information and resources, the new TheraSphere.com website is
the global hub that connects our users to a complete suite of training
and support, whether they’re administrating their first TheraSphere®
dose or their 100th.”
Specifically for physicians, the site offers convenient online access to
a suite of unique TheraSphere® resources, including:
Preceptor Program: Connects physicians with experienced
interventional radiologists that provide medical and technical advice
to treatment users.
Resource Center iPad App: A comprehensive educational tool
designed for healthcare professionals, placing valuable product
information at their fingertips.
Ordering for Standard and Custom Doses: TheraSphere® users can
order product online or by email, phone or fax. This includes custom
doses, which are designed to provide greater treatment flexibility for
physicians, save administration time and reduce product waste.
clinical trial information: Up-to-date information on
TheraSphere® Phase III clinical trials, which include YES-P (liver
cancer patients with portal vein thrombosis) STOP-HCC (patients with
hepatocellular carcinoma) and EPOCH (patients with colorectal cancer
whose disease has metastasized to the liver).
In addition to the TheraSphere®
animation video and comprehensive Patient
Information Guide, liver cancer patients and caregivers around the
world can now find product information in their language, on dedicated
pages offering quick access to treatment centers and resources specific
to their location.
The new TheraSphere.com
website is optimized for mobile devices and all modern browsers, to meet
the needs of users on the go, on their platform of choice.
Visitors can also follow @NordionInc
on Twitter to keep up-to-date on TheraSphere® news and upcoming events,
and can subscribe to the Nordion
YouTube channel for the latest video content.
To learn more, visit the Nordion booth at the following interventional
oncology industry events:
SSO – Society of Surgical Oncology Cancer Symposium
Gaylord National Hotel
March 6 - 9, 2013
SIR – Society of Interventional Radiology
New Orleans, LA
N. Morial Convention Center
April 13 - 18, 2013
TheraSphere® is a liver
cancer therapy that consists of millions of small glass beads (20 to
30 micrometers in diameter) containing radioactive
Y-90. The product is injected by physicians into the artery of the
patient’s liver through a catheter, which allows the treatment to be
delivered directly to the tumour via blood flow.
In the US, TheraSphere® is used to treat patients with hepatocellular
carcinoma (HCC) who can have appropriately positioned hepatic
arterial catheters, and can be used as a bridge to surgery or
transplantation in these patients. It is also indicated for the
treatment of HCC patients with partial or branch portal vein thrombosis
or occlusion when clinical evaluation warrants the treatment. TheraSphere®
is approved by the U.S. Food and Drug Administration (FDA) under a
Humanitarian Device Exemption (HDE). HDE approvals are based on
demonstrated safety and probable clinical benefit. However,
effectiveness of the indication for use has not been established.
TheraSphere® is used in the European Union and in Canada for
the treatment of hepatic neoplasia in patients who have appropriately
positioned arterial catheters.
Common side effects include mild to moderate fatigue, pain and nausea
for about a week. Physicians describe these symptoms as similar to those
of the flu. Some patients experience some loss of appetite and temporary
changes in several blood tests. For details on rare or more severe side
effects, please refer to the TheraSphere® Package
Insert/Instructions for Use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company
that provides market-leading products used for the prevention, diagnosis
and treatment of disease. We are a leading provider of targeted
technologies and medical
isotopes that benefit the lives of millions of people in more than
60 countries around the world. Our products are used daily by
pharmaceutical and biotechnology companies, medical-device
manufacturers, hospitals, clinics and research laboratories. Nordion has
approximately 500 highly skilled employees worldwide. Find out more at www.nordion.com
and follow us at http://twitter.com/NordionInc.
Source: Nordion Inc.
Shelley Maclean, 613-592-3400 x.